# UroGen Pharma

Source: https://onco.cc/companies/urogen-pharma/  
OnCo record `urogen-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UroGen Pharma is a United States-based pharmaceutical company running 3 late-stage cancer trials of UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer.

## Summary

UroGen Pharma, based in Princeton, NJ, the United States, is a pharmaceutical company listed as NASDAQ: URGN. UroGen Pharma develops treatments for urothelial and specialty cancers, including its FDA-approved therapies Zusduri and Jelmyto, based on its proprietary RTGel reverse-thermal hydrogel technology. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer. The largest, NCT05243550 (A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer), plans to enrol 240 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: UroGen Pharma Ltd.
- Tags: ctgov-sponsor
- HQ: Princeton, NJ
- Type: pharma
- Website: https://www.urogen.com
- Ticker: NASDAQ: URGN

## Sources

- Official website: https://www.urogen.com
- ClinicalTrials.gov: trials led by UroGen Pharma: https://clinicaltrials.gov/search?lead=UroGen%20Pharma%20Ltd.
- Pipeline page: https://www.urogen.com/pipeline

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [UGN-103](https://onco.cc/drugs/ugn-103/), [UGN-104](https://onco.cc/drugs/ugn-104/)
- trials: [A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer](https://onco.cc/trials/nct05243550/), [A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer](https://onco.cc/trials/nct06774131/), [A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer](https://onco.cc/trials/nct06331299/)

---
JSON: https://onco.cc/api/v1/entities/urogen-pharma.json